At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/1b Pharmacokinetics Study of Oral MLN9708 in Patients With Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors With Normal Renal Function or Severe Renal Impairment
In Brief
A Phase 1 clinical trial evaluating Ixazomib for Multiple Myeloma and Advanced Solid Tumors. Completed, enrolled 41 participants across 11 sites in 2 countries.
Detailed Summary
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants with end-stage renal disease (ESRD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Advanced Solid Tumors
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartSep 2013
Primary CompletionMar 2015
Study CompletionNov 2016
TodayJul 2026
First PostedApr 12, 2013
Enrollment StartSep 16, 2013
Primary CompletionMar 3, 2015
Study CompletionNov 18, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.2 years ago
Interventions
Ixazomibdrug
Ixazomib capsules